Non-invasive therapy to reduce brain damage after a stroke
Non-invasive mitochondrial modulation therapy for ischemic stroke
This study is testing a new, gentle therapy that uses special light to help protect the brain after a stroke by improving how brain cells work, and it's designed to be safe and easy for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11015014 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapy that uses near-infrared light to modulate mitochondrial activity in the brain during the critical phase after a stroke. By targeting the mitochondria, the therapy aims to reduce the harmful production of reactive oxygen species that can occur when blood flow is restored to the brain. The approach is non-invasive, meaning it does not require surgical procedures, making it potentially safer and easier for patients. The goal is to limit the damage caused by ischemia-reperfusion injury, which is a common complication following a stroke.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced an ischemic stroke and are within the appropriate time frame for intervention.
Not a fit: Patients who have not experienced a stroke or those with other types of brain injuries may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces brain damage and improves recovery outcomes for stroke patients.
How similar studies have performed: While the approach of using light to modulate mitochondrial activity is innovative, similar strategies targeting mitochondrial function have shown promise in other contexts, suggesting potential for success in this area.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Sanderson, Thomas Hudson — University of Michigan at Ann Arbor
- Study coordinator: Sanderson, Thomas Hudson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.